Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Maria Fleseriu; Beverly M K Biller; James W Findling; Mark E Molitch; David E Schteingart; Coleman Gross; SEISMIC Study Investigators; Timothy Lyons

doi:10.1210/jc.2011-3350

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Maria Fleseriu
, Beverly M K Biller
, James W Findling
, Mark E Molitch
, David E Schteingart
, Coleman Gross
, SEISMIC Study Investigators
, Timothy Lyons

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

415 Citations (Scopus)

Abstract

Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.

Original language	English
Pages (from-to)	2039-49
Number of pages	11
Journal	The Journal of clinical endocrinology and metabolism
Volume	97
Issue number	6
DOIs	https://doi.org/10.1210/jc.2011-3350
Publication status	Published - Jun 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adult
Antihypertensive Agents
Blood Glucose
Blood Pressure
Body Composition
Body Weight
Cushing Syndrome
Diabetes Mellitus, Type 2
Female
Glucose Intolerance
Hormone Antagonists
Humans
Hydrocortisone
Hypertension
Male
Middle Aged
Mifepristone
Quality of Life
Quinolines
Receptors, Glucocorticoid
Urea

Access to Document

10.1210/jc.2011-3350

Cite this

Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., SEISMIC Study Investigators, & Lyons, T. (2012). Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. The Journal of clinical endocrinology and metabolism, 97(6), 2039-49. https://doi.org/10.1210/jc.2011-3350

@article{f2f14cb86c1d4860a591e56e7da2b15e,

title = "Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome",

abstract = "Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.",

keywords = "Adult, Antihypertensive Agents, Blood Glucose, Blood Pressure, Body Composition, Body Weight, Cushing Syndrome, Diabetes Mellitus, Type 2, Female, Glucose Intolerance, Hormone Antagonists, Humans, Hydrocortisone, Hypertension, Male, Middle Aged, Mifepristone, Quality of Life, Quinolines, Receptors, Glucocorticoid, Urea",

author = "Maria Fleseriu and Biller, \{Beverly M K\} and Findling, \{James W\} and Molitch, \{Mark E\} and Schteingart, \{David E\} and Coleman Gross and \{SEISMIC Study Investigators\} and Timothy Lyons",

year = "2012",

month = jun,

doi = "10.1210/jc.2011-3350",

language = "English",

volume = "97",

pages = "2039--49",

journal = "The Journal of clinical endocrinology and metabolism",

issn = "0021-972X",

publisher = "Endocrine Society",

number = "6",

}

Fleseriu, M, Biller, BMK, Findling, JW, Molitch, ME, Schteingart, DE, Gross, C, SEISMIC Study Investigators & Lyons, T 2012, 'Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome', The Journal of clinical endocrinology and metabolism, vol. 97, no. 6, pp. 2039-49. https://doi.org/10.1210/jc.2011-3350

TY - JOUR

T1 - Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

AU - Fleseriu, Maria

AU - Biller, Beverly M K

AU - Findling, James W

AU - Molitch, Mark E

AU - Schteingart, David E

AU - Gross, Coleman

AU - SEISMIC Study Investigators

AU - Lyons, Timothy

PY - 2012/6

Y1 - 2012/6

N2 - Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.

AB - Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.

KW - Adult

KW - Antihypertensive Agents

KW - Blood Glucose

KW - Blood Pressure

KW - Body Composition

KW - Body Weight

KW - Cushing Syndrome

KW - Diabetes Mellitus, Type 2

KW - Female

KW - Glucose Intolerance

KW - Hormone Antagonists

KW - Humans

KW - Hydrocortisone

KW - Hypertension

KW - Male

KW - Middle Aged

KW - Mifepristone

KW - Quality of Life

KW - Quinolines

KW - Receptors, Glucocorticoid

KW - Urea

U2 - 10.1210/jc.2011-3350

DO - 10.1210/jc.2011-3350

M3 - Article

C2 - 22466348

SN - 0021-972X

VL - 97

SP - 2039

EP - 2049

JO - The Journal of clinical endocrinology and metabolism

JF - The Journal of clinical endocrinology and metabolism

IS - 6

ER -

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this